GeneDx beat Q2 estimates, raised guidance, and is seeing rapid test volume growth and stronger reimbursements. Check out why ...

The most assertive raise of the three came from BTIG's Mark Massaro, who now feels GeneDx is worth $125 per share, well up ...

That earnings report, unveiled well before market open that day, revealed that GeneDx booked nearly $103 million in revenue.

Management raised full-year 2025 total revenue guidance to $400 million–$415 million and exome/genome revenue growth guidance to 48%–52%, with expected exome and genome revenue of $345 million–$355 ...